GSE19470   Details

GSE Accession GSE19470
Title Expression data from patients presenting with a first demyelinating event (early multiple sclerosis)
Submission Date 12/14/09
Last Update Date 3/21/12
Pubmed ID
Experiment Type Expression profiling by array
Contributor Victoria,M,Perreau; Olga Skibina; Yifang Hu; Michele,D,Binder; Judith Field; Helmut Butzkueven; Gordon Smyth; Trevor,J,Kilpatrick
Contact Name
Contact E-mail
Organization Name
Organism ID
Organism Synonym
Summary The ability to predict disease course in multiple sclerosis currently relies upon MRI evaluation to provide an estimate of risk of subsequent outcome. Molecular determinants of risk remain largely unexplored; however, the identification of accurate molecular predictors at presentation of a first demyelinating event (FDE) would complement MRI in identifying patients likely to benefit from aggressive treatment. Information concerning the molecular profiles that are important in driving risk of subsequent activity at disease onset could also indicate cellular activation instigated at disease onset. We conducted a genome-wide gene expression profiling (GEP) study of CD3+ T cells from 11 patients at FDE compared to matched controls. Samples were obtained from each patient at both the FDE and a time point 3 months later when disease was predicted to remit in a subset of patients; this was emulated in the control population. Patients were stratified into 2 groups (inactive and active) based upon clinical and neuroimaging-based activity at the 3-month time-point.
Overall Design Blood samples were taken from 11 patients at time of presenting with a first demyelinating event and at a three-month-later time point. Age- and gender-matched controls were collected contemporaneously for all subjects and time points. Total RNA was extracted from CD3+ cells purified from whole blood samples immediately following collection and stored at -80 degC. Total RNA samples were later processed for hybridization to Affymetrix Human Exon 1.0 ST array in two balanced batches. Clinical assessment and MRI results of patients at presentation and at the 3-month time point were used to to segregate the patients into two groups; patients with active disease versus patients with inactive disease at the 3-month follow-up.
Platform ID
Timepoint Count 0
Disease ID